Last reviewed · How we verify
NCT04848675
Novel Time-efficient Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure
NA trial testing Inspiratory muscle strength training in Blood Pressure in 102 participants. Status unknown.
1 May 2025
Quick facts
| Lead sponsor | University of Colorado, Boulder |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 7 May 2021 |
| Primary completion | 1 May 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Inspiratory muscle strength training
- Brisk walking
Conditions studied
- Blood Pressure — all drugs for Blood Pressure →
- Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
- Hypertension — all drugs for Hypertension →
Sponsor
University of Colorado, Boulder
Who can join
50 and older, any sex, with Blood Pressure or Endothelial Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Above-normal systolic blood pressure (SBP), defined as SBP \>/= 120 mmHg, is the major modifiable risk factor for cardiovascular disease, stroke, cognitive decline/dementia, and other chronic health problems. Despite the availability of treatments to lower SBP, over 75 percent of adults with above-normal SBP fail to control BP, which has led to a nearly 50 percent increase in the number of deaths attributable to BP over the past decade. Therefore, above-normal SBP is a major public health burden. * Greater than 65 percent of adults 50 years of age and older have above-normal SBP. The number of adults age 50 years and older is rapidly increasing, predicting a continued increase in above-normal SBP driven morbidity and mortality in the absence of effective treatment strategies. This makes developing novel SBP-lowering therapies an urgent biomedical research priority. * Increasing SBP is closely linked to vascular dysfunction, observable as impaired endothelial function, increased large-elastic artery stiffness, and impaired cerebrovascular function. Declines in these functions play a large role in the increased risk of chronic disease associated with above-normal SBP. The primary mechanism responsible for SBP-induced vascular dysfunction is thought to be oxidative stress-associated inhibition of nitric oxide bioavailability. Therefore, to have the largest biomedical impact, new SBP-lowering therapies should also improve vascular function by decreasing oxidative stress. * Healthy lifestyle practices, such as conventional aerobic exercise, maintaining a healthy diet, or reducing sodium intake, are all first-line strategies to lower SBP. Importantly, these lifestyle practices also improve vascular function, in large part by reducing oxidative stress. However, adherence to healthy lifestyle practices is poor, with adherence to guidelines generally between 20 to 40 percent in adult Americans. The greatest reported barrier to meeting healthy lifestyle guidelines is lack of time. Therefore, time-efficient interventions have great promise for promoting adherence, reducing SBP, and improving other physiological functions. * High-resistance inspiratory muscle strength training (IMST) is a time-efficient (5 minutes per session) lifestyle intervention consisting of 30 inspiratory maneuvers performed against a high resistance. Preliminary data suggest 6-weeks of IMST performed 6 days/week reduces SBP by 9 mmHg in adults with above-normal SBP (i.e., greater than 120 mmHg) at baseline. Importantly, this reduction in SBP is equal to or greater than the reduction in blood pressure typically achieved with time- and effort-intensive healthy lifestyle strategies like conventional aerobic exercise. However, these results need to be confirmed in an appropriately powered clinical trial with a longer, guideline-based treatment duration. Furthermore, the influence of IMST on functions impaired by above-normal SBP (endothelial, cerebrovascular, cognitive) needs to be determined, as do the mechanisms through which IMST exerts beneficial effects. * Accordingly, we will conduct a randomized, blinded, sham-controlled, parallel group design clinical trial to assess the efficacy of 3-months of IMST (75 percent maximal inspiratory pressure) vs. brisk walking (40-60% heart rate reserve; an established healthy lifestyle strategy) for lowering SBP and improving endothelial, cerebrovascular, and cognitive function in adults age 50 years and older with above-normal SBP. I hypothesize IMST will lower SBP and improve endothelial function by decreasing oxidative stress and increasing nitric oxide bioavailability. I also hypothesize IMST will improve cerebrovascular and cognitive function, and that these improvements will be related to reductions in SBP and improvements in endothelial function. I also expect adherence to the intervention to be excellent (over 80 percent of all training sessions completed at the appropriate intensity). * To test my hypothesis, I will recruit 102 adults age 50 years and older who have SBP \>/= 120 mmHg. Subjects will undergo baseline testing for casual (resting) SBP, 24-hour ambulatory SBP, endothelial function, arterial stiffness, cognitive function, and cerebrovascular function. Innovative mechanistic probes including pharmaco-dissection with vitamin C, analysis of biopsied endothelial cells, and high-throughput metabolomics, will be performed to assess oxidative stress and nitric oxide bioavailability at baseline. * After baseline testing, subjects will be randomized to perform either 3-months of high-resistance IMST or brisk walking. Subjects will train 6 days/week with one training session supervised in the laboratory and the other 5 performed unsupervised at home. Following 3 months of training, subjects will redo all the tests that were done during baseline testing to assess training-induced changes in SBP, physiological functions, and underlying mechanisms.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Aging, aerobic exercise, and cardiovascular health: Barriers, alternative strategies and future directions.
Murray KO, Mahoney SA, Venkatasubramanian R, Seals DR, et al · · 2023 · cited 32× · PMID 36731386 · DOI 10.1016/j.exger.2023.112105 -
Promoting healthy cardiovascular aging: emerging topics.
Clayton ZS, Craighead DH, Darvish S, Coppock M, et al · · 2022 · cited 19× · PMID 36337728 · DOI 10.20517/jca.2022.27 -
Time-efficient, high-resistance inspiratory muscle strength training increases cerebrovascular reactivity in midlife and older adults.
Freeberg KA, Craighead DH, Heinbockel TC, Rossman MJ, et al · · 2023 · cited 13× · PMID 37682232 · DOI 10.1152/ajpheart.00351.2023 -
Translational Potential of High-Resistance Inspiratory Muscle Strength Training.
Craighead DH, Freeberg KA, Maurer GS, Myers VH, et al · · 2022 · cited 10× · PMID 35394978 · DOI 10.1249/jes.0000000000000293 -
Sex Differences in Dementia and Mild Cognitive Impairment in Nondialysis CKD.
Oh ES, Opoku G, Darvish S, Craighead DH, et al · · 2026 · PMID 41264372 · DOI 10.2215/cjn.0000000922
Verify or expand the search:
- PubMed search for NCT04848675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Inspiratory muscle strength training
Trials testing the same drug.
- NCT05938127 — Impact of Respiratory Training in Lymphoma Survivors · NA · terminated
- NCT05744817 — Reduced Volume of Inspiratory Resistance Training · NA · withdrawn
- NCT06091384 — Inspiratory Muscle Strength Training in Post-Covid Syndrome · NA · unknown
- NCT04832165 — Inspiratory Muscle Training on Diaphragm Thickness, Inspiratory Muscle Pressure and Physical Function · NA · completed
- NCT03501355 — Effects of Inspiratory Muscle and Endurance Training in Heart Failure Patients With Pacemaker · NA · completed
Other recruiting trials for Blood Pressure
Currently open trials in the same condition.
- NCT07070583 — Impact of Aorto-Iliac Occlusive Disease Treatment on Blood Pressure · NA · recruiting
- NCT07396636 — Machine Learning-Assisted Management of Intraoperative Hypotension for Personalized Treatment · recruiting
- NCT06719518 — Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device · recruiting
- NCT07319117 — Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure. · NA · recruiting
- NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
Other University of Colorado, Boulder trials
Trials by the same sponsor.
- NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
- NCT07011160 — Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults · NA · not yet recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT06588582 — Perceptual Influences From Smoking Cannabis: an Experimental Study · NA · recruiting
- NCT06769022 — Exercise Adherence and Cognitive Decline · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04848675 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Boulder
- Last refreshed: 2 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04848675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing